ResumoObjetivos: Estimar a frequência da não adesão ao tratamento medicamentoso entre idosos acompanhados ambulatorialmente, bem como analisar seus fatores associados. Metodologia: Foi conduzido estudo transversal com 263 idosos atendidos no ambulatório de especialidades médicas de um hospital filantrópico, localizado no município de Vitória-ES. Foi realizada entrevista utilizando roteiro estruturado em três blocos que contemplavam questões sociodemográficas, condições de saúde e estilo de vida e medicamentos em uso. Para verificar a não adesão ao tratamento medicamentoso, foi aplicado o instrumento de Medida de Adesão Terapêutica (MAT). Os dados foram analisados por meio do teste Qui-quadrado para variáveis categóricas. Foram consideradas significativas as variáveis com valor de p<0,05 no modelo final de regressão múltipla de Poisson. Resultados: Os resultados mostraram uma frequência de não adesão ao tratamento medicamentoso de 26,7% da amostra. A não adesão ao tratamento medicamentoso nessa população se mostrou positivamente associada à ausência de vínculo empregatício anterior a aposentadoria (RP=1,12; p<0,010); presença de declínio cognitivo (RP=1,13; p<0,010) e hábitos alimentares inadequados (RP=1,12; p<0,005). Conclusão: Com o estudo, foi possível identificar os fatores associados à não adesão medicamentosa nos idosos investigados e assim contribuir para o conhecimento do perfil sociodemográfico, condições de saúde e estilo de vida e características relacionadas à utilização de medicamentos por parte dessa população. AbstractObjectives: To estimate the non-adherence frequency of drug treatment among elderly outpatients and to analyze associated factors. Methods: A cross-sectional study was conducted with 263 elderly patients from the medical specialties outpatient of a philanthropic hospital, located in the city of Vitoria, Espirito Santo state, Brazil.Palavras-chave: Adesão à Medicação. Idoso. Terapêutica. Assistência Ambulatorial.http://dx
Presarcopenia and sarcopenia were evaluated in HIV-infected individuals and in healthy elderly controls according to the consensus definitions of the European Working Group on Sarcopenia in Older People. Bioelectrical impedance, a hydraulic hand dynamometer, and gait speed were used to evaluate muscle mass, muscle strength, and physical performance, respectively. Adjusted and unadjusted binary logistic regression predicted the risk of sarcopenia. Predictor contribution was assessed by the Wald test. Significance was established at p≤0.05. The HIV-infected group consisted of 33 patients on treatment (42.4% women; mean age 59±7 years; mean BMI 25±6kg/m(2); viral load undetectable in 30 cases). The HIV-uninfected group consisted of 60 individuals (71.7% women; mean age 70±7 years; mean BMI 28±6kg/m(2)). Of the controls, 4 (6.7%) individuals had presarcopenia and 4 (6.7%) sarcopenia compared to 4 (12.1%) and 8 (24.2%), respectively, in the HIV-infected group. The HIV-infected patients had a 4.95 higher risk (95% CI: 1.34-18.23) for sarcopenia compared to the controls. It should be pointed out that the control group was on average 10 years older. This risk increased further (RR=5.20; 95% CI: 1.40-19.20) after adjusting for age and BMI. HIV-infected patients were shown to be at a greater risk of sarcopenia, an indicator of frailty, even following adjustment for age and BMI.
Late-onset Alzheimer's disease (LOAD) is a multifactorial neurodegenerative disorder that corresponds to most Alzheimer's disease (AD) cases. Inflammation is frequently related to AD, whereas microglial cells are the major phagocytes in the brain and mediate the removal of Aβ peptides. Microglial cell dsyregulation might contribute to the formation of amyloid plaques, a hallmark of AD. Genome-wide association studies have reported genetic loci associated with the inflammatory pathway involved in AD. Among them, rs3865444 CD33, rs3764650 ABCA7, rs6656401 CR1, and rs610932 MS4A6A variants in microglial genes are associated with LOAD. These variants are proposed to participate in the clearance of Aβ peptides. However, their association with LOAD was not validated in all case-control studies. Thus, the present work aimed to assess the involvement of CD33 (rs3865444), ABCA7 (rs3764650), CR1 (rs6656401), and MS4A6A (rs610932) with LOAD in a sample from southeastern Brazil. The genotype frequencies were assessed in 79 AD patients and 145 healthy elders matched for sex and age. We found that rs3865444 CD33 acts as a protective factor against LOAD. These results support a role for the inflammatory pathway in LOAD.
Introduction Stroke is the most common cause of disability in Western countries, yet there is no consensus in the literature on how to measure and describe disability from stroke. Objective To conduct a systematic literature review on disability in stroke survivors. Method Observational studies published in the PubMed, LILACS and SciELO online databases were selected, to evaluate disability in adults and in the elderly after stroke in the period 2002–2012. The Downs and Black checklist for non-randomized studies was used to assess the quality of the articles. Results 212 articles were found from which 16 were selected to compose the study. The mean age of participants was 67 years, and disability affected 24% to 49% of the population evaluated. With regard to measurement instruments, 31% of the studies analyzed presented results of disability by means of the modified Rankin Scale; 19% by means of the World Health Organization’s International Classification of Functioning, Disability and Health; 19% by means of Katz’ Index of Independence in Activities of Daily Living; 12.5% by means of the London Handicap Scale; 12.5 % by means of the Barthel Index; and 6.25% by means of the Functional Independence Measure. Conclusion Literature is not uniform as regards means of measuring disability after stroke, but considering the preference of articles in assessing physical performance in activities of daily living, it can be concluded that a quarter to half of the population that survives stroke has some degree of disability.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.